文献速递胸部肿瘤

阿法替尼联合西妥昔单抗治疗EGFR外显子20插入阳性晚期NSCLC四例

Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
PubMed 文献 · J Thorac Oncol · 2018-04-24

本文报告4例EGFR外显子20插入阳性晚期肺腺癌患者,接受阿法替尼40mg每日一次联合西妥昔单抗250-500mg/m2每两周一次治疗。3/4例获部分缓解,中位无进展生存期5.4个月(95%CI 0.0-14.2),毒性可控。提示双靶向EGFR阻断可能诱导该类患者肿瘤缓解。

要点

  • EGFR外显子20插入占EGFR突变NSCLC的4%-9%,对EGFR-TKI原发耐药。
  • 阿法替尼联合西妥昔单抗在4例中3例达部分缓解。
  • 中位无进展生存期5.4个月,毒性经皮肤管理和减量可控。

核心结论

  • 阿法替尼联合西妥昔单抗双靶向EGFR阻断可能诱导EGFR外显子20插入阳性NSCLC患者肿瘤缓解。

研究设计与样本

  • 本文为病例系列,纳入4例EGFR外显子20插入阳性晚期NSCLC患者。
  • 治疗方案为阿法替尼40mg每日一次联合西妥昔单抗250mg/m2至500mg/m2每两周一次。

主要发现

  • 4例均为IV期肺腺癌,携带EGFR外显子20插入突变。
  • 既往治疗包括含铂双药化疗(n=4)和EGFR-TKI(n=2)。
  • 4例中3例按RECIST 1.1标准达部分缓解。
  • 中位无进展生存期5.4个月(95%CI 0.0-14.2个月;范围2.7-17.6个月)。
  • 毒性可控,2例需减量,并需适当皮肤管理。

关键数值与推荐

  • EGFR外显子20插入占EGFR突变NSCLC的4%至9%。
  • 阿法替尼剂量为40mg每日一次,西妥昔单抗为250mg/m2至500mg/m2每两周一次。
  • 疗效评价采用RECIST 1.1标准。

临床怎么用

  • 对EGFR外显子20插入阳性晚期NSCLC,可考虑阿法替尼联合西妥昔单抗作为治疗选择。
  • 治疗期间需进行皮肤毒性管理,必要时减量。

局限性

  • 样本量仅4例,证据级别有限。
  • 无对照组,结论需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: EGFR exon 20 insertions comprise 4% to 9% of EGFR mutated NSCLC. Despite being an oncogenic driver, they are associated with primary resistance to EGFR tyrosine kinase inhibitors (TKIs). We hypothesized that dual EGFR blockade with afatinib, an irreversible EGFR TKI, and cetuximab, a monoclonal antibody against EGFR, could induce tumor responses. METHODS: Four patients with EGFR exon 20 insertion-positive NSCLC were treated with afatinib 40 mg once daily and cetuximab 250 mg/m2 to 500 mg/m2 every 2 weeks. RESULTS: All patients had stage IV adenocarcinoma of the lung harboring an EGFR exon 20 insertion mutation. Previous lines of treatment consisted of platinum doublet chemotherapy (n = 4) and EGFR TKI (n = 2). Three of four patients showed a partial response according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Median progression-free survival was 5.4 months (95% confidence interval: 0.0 - 14.2 months; range 2.7 months - 17.6 months). Toxicity was manageable with appropriate skin management and dose reduction being required in two patients. CONCLUSIONS: Dual EGFR blockade with afatinib and cetuximab may induce tumor responses in patients with EGFR exon 20 insertion-positive NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. van Veggel B, de Langen AJ, Hashemi SMS, et al. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC. J Thorac Oncol. 2018. PMID: 29702285. doi:10.1016/j.jtho.2018.04.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。